Skip to main content

Table 7 Cut-off of 90% sensitivity of the markers in subjects with tPSA 4–10 ng/mL

From: Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study

Marker Cut-off at 90% sensitivity % Specificity Unnecessary biopsy avoided Missed cancer
Total Missed GS 6 Missed GS 7 Missed GS ≥ 8
Total PSA 4–10 ng/mL
%fPSA ≤ 7.86 9% 4
(5.2%)
3 (10.3%) 0
(0%)
1 (3.5%) 2 (6.8%)
p2PSA
(pg/mL)
≥ 8.08 17% 7
(9.1%)
3 (10.3%) 2
(6.8%)
0
(0%)
1 (3.5%)
%
p2PSA
≥ 1.20 27% 12
(15.5%)
3 (10.3%) 3 (10.3%) 0
(0%)
0
(0%)
PHI ≥ 26.33 25% 9
(11.7%)
2
(6.8%)
2
(6.8%)
0
(0%)
0
(0%)
All study subjects
%fPSA ≤ 6.42 7% 6
(4.3%)
7 (11.1%) 0
(0%)
2 (3.2%) 5 (7.9%)
p2PSA
(pg/mL)
≥ 8.07 20% 16
(11.4%)
7 (11.1%) 4
(6.3%)
2 (3.2%) 1 (1.6%)
%
p2PSA
≥ 1.22 31% 24
(17.1%)
7 (11.1%) 7 (11.1%) 0
(0%)
0
(0%)
PHI ≥ 33.40 40% 32
(22.9%)
5
(7.9%)
5
(7.9%)
0
(0%)
0
(0%)
  1. PSA, prostate-specific antigen; fPSA, free PSA; p2PSA, [-2]proPSA; PHI, prostate health index
  2. Bold types to represent clinical significance could avoid unnessasary biopsies for %p2SPA and PHI